EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Nissan (NISA) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Nissan ILS 16.51, price ILS 9.34, upside +76.7%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · Il · ISIN IL0006600196

N Some data Sep 24, 2026

Nissan

NISA · TA

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value 16.51 ILA · Strongly undervalued (+77%)
!Quality 46/100
!Weak Growth (revenue 5y −2.0 %/yr)
!Thin margins · 0.6% net margin (TTM)
✓Low debt · generates free cash flow
·0.23% dividend yield
!Mixed vs. peers (6/14)
!Narrow moat 25/100
!Evidence only medium, so the estimate is less certain
!Weak on past: 10 out of 100
!Weak on dividend: 5 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

24.21 ILA 5.93 ILA Fair Value 16.51 ILA May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 5.93 ILA – 24.21 ILA · fair‑value band 12.89 ILA – 18.50 ILA · the 9.34 ILA price screens below the 16.51 ILA fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Nissan in your weekly email

Every Wednesday you see whether Nissan is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nissan Medical Industries Ltd manufactures and markets spunlace non-woven fabrics in the United States, Canada, Europe, the Far East, Israel, and internationally. Its products are used in reusable and consumable consumer products, medical products, automotive, infrastructure, hygienic, and other industries.

Show more

Nissan Medical Industries Ltd manufactures and markets spunlace non-woven fabrics in the United States, Canada, Europe, the Far East, Israel, and internationally. Its products are used in reusable and consumable consumer products, medical products, automotive, infrastructure, hygienic, and other industries. The company sells its products through its sales agents. Nissan Medical Industries Ltd was incorporated in 1984 and is based in Tel Aviv-Yafo, Israel.

Stock analysis

Nissan (NISA) currently trades at 9.34 ILA, while our model-based Fair Value estimate is 16.51 ILA, implying the stock looks roughly 43.4% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 37.99 ILA per share, and 20 of the 24 models we run sit above the 9.34 ILA price.

Bear case: the Earnings-Based group reads lowest at 5.97 ILA, and 4 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: 12.89 ILA (bear) to 18.50 ILA (bull), the price of 9.34 ILA sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Nissan reported revenue of 652M ILS in FY2025 versus 668M ILS in FY2021, a compound −0.6%/yr. Reported net income was 4.2M ILS in FY2025, compounding −41.7%/yr from FY2021.

Key figures

Market cap 84.9M ILA · P/E ratio 21.7 · P/S ratio 0.14 · EPS (TTM) 0.4300 ILA · Dividend yield 0.2% · Net margin 0.6% · Return on equity 2.5% · Return on assets (EBIT) 4.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 77%, NISA screens cheaper than that median.

Fair Value models

Bear 12.89 ILA Fair Value 16.51 ILA Bull 18.50 ILA
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.3157 ILS per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 40.80 ILA 56.05 ILA 79.77 ILA 81
Growth DCF 42.18 ILA 56.70 ILA 78.00 ILA 79
Owner Earnings 17.88 ILA 24.93 ILA 35.91 ILA 77
All 24 models by family
DCF Models
FCF DCF 40.80 ILA 56.05 ILA 79.77 ILA 81
Owner Earnings 17.88 ILA 24.93 ILA 35.91 ILA 77
5Y Revenue Exit 27.02 ILA 37.18 ILA 50.44 ILA 73
5Y EBITDA Exit 43.31 ILA 65.30 ILA 91.64 ILA 75
5Y P/E Exit 18.61 ILA 22.65 ILA 26.95 ILA 72
10Y Revenue Exit 31.52 ILA 41.20 ILA 52.14 ILA 68
10Y EBITDA Exit 41.94 ILA 59.50 ILA 79.89 ILA 69
10Y P/E Exit 27.02 ILA 31.75 ILA 36.32 ILA 65
Earnings-Based
Graham-Dodd 3.12 ILA 5.97 ILA 7.45 ILA 66
EPV 17.73 ILA 20.82 ILA 23.49 ILA 74
Dividend Discount
Gordon GGM 15.98 ILA 21.67 ILA 27.28 ILA 69
DDM Multi-Stage 15.98 ILA 21.86 ILA 28.51 ILA 67
Multiples
P/E Multiple 7.58 ILA 10.11 ILA 12.63 ILA 63
P/S Multiple 5.86 ILA 7.81 ILA 9.76 ILA 58
P/B Multiple 5.86 ILA 7.81 ILA 9.76 ILA 55
EV/EBIT 28.67 ILA 38.85 ILA 49.04 ILA 66
EV/EBITDA 52.04 ILA 70.01 ILA 87.98 ILA 67
EV/Revenue 19.93 ILA 29.27 ILA 38.61 ILA 53
Asset-Based
NCAV (Graham) 10.66 ILA 14.29 ILA 21.32 ILA 54
Growth DCF
Growth DCF 42.18 ILA 56.70 ILA 78.00 ILA 79
Rev-Margin DCF 27.02 ILA 37.99 ILA 50.75 ILA 73
Economic Profit
Residual Income 14.97 ILA 14.42 ILA 11.42 ILA 76
ROIC Compounder 17.73 ILA 20.82 ILA 24.29 ILA 72
Growth Earnings
Growth-Adj P/E 5.42 ILA 7.75 ILA 10.07 ILA 67

Open the full fair value analysis →

Notify me when NISA reaches fair value

Put NISA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 45 · Market factors (momentum, volatility) 58

Profitability 33
Margins and returns on capital today
Quality Growth 45
Are margins and returns improving?
Cashflow 47
Earnings quality: real cash, not paper profit
Fin. Strength 29
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 86
Calm price path (market factor)
Momentum 47
Price trend over the last 3–12 months (market factor)
52W Momentum 46
Distance to the 52-week high (market factor)
Net Issuance 42
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Start year 2020 (pandemic). Over 10 years: +2.1% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−34.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−35.0%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−35% vs −14%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 3%
Start year 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −4.2% a year for the price.

Watch NISA, get fair value alerts →

Compare Nissan with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside +75% · Top 25%
Profitability
Return on equity (TTM) 3% · Below median
Return on assets 2% · Below median
Net margin (TTM) 1% · Bottom 25%
Operating margin (TTM) −2% · Bottom 25%
Growth and dividend
Revenue growth −8% · Bottom 25%
Dividend yield (TTM) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 21.7× · Cheaper than median
P/B 0.15× · Cheapest 25%
P/S (TTM) 0.04× · Cheapest 25%
P/FCF 1.2× · Cheapest 25%
EV/EBITDA 1.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 17
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)10 · sector 25
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)5 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.50 €158.95 +10%
Medline Inc MDLN $34.43 $30.15 −12%
Becton, Dickinson and Company BDX $183.00 $103.53 −43%
Alcon Inc ALC $65.59 $39.78 −39%
ResMed Inc RMD A$31.61 A$34.77 +10%
West Pharmaceutical Services, Inc WST $371.09 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €206.40 €54.82 −73%
Straumann Holding STMN CHF 97.86 CHF 45.50 −54%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Nissan Fair Value". https://www.fairvalue-calculator.com/stock/NISA

Frequently asked questions

Is Nissan (NISA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 16.51 ILA versus a price of 9.34 ILA, about +77% upside (undervalued).
What is the fair value of NISA?
Our model-based fair value for Nissan is 16.51 ILA (as of Sep 24, 2026), built from audited fundamentals. The current price: 9.34 ILA.
What is the quality score of NISA?
Nissan has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nissan (NISA)?
Our model-based price target is the fair value of 16.51 ILA (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 12.89 ILA, optimistic scenario 18.50 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Nissan stock forecast for 2026?
Our models put fair value at 16.51 ILA, about +77% upside versus a price of 9.34 ILA (undervalued). Cautious scenario 12.89 ILA, optimistic scenario 18.50 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Nissan (NISA)?
Nissan reported trailing-twelve-month revenue of about 640M ILS (latest available figure, as of Sep 24, 2026).
Does Nissan pay a dividend?
Nissan currently shows a dividend yield of about 0.23% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Nissan (NISA)?
For today's price to be fair in a discounted-cash-flow model, Nissan would have to grow free cash flow by -2.2 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of NISA use?
Our models discount Nissan at 10.1 %: a base by market capitalisation (nano), damped by beta 0.06, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nissan that is -2.2 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Nissan (NISA) delivered so far?
Over the past 5 years revenue at Nissan grew -2.0 % a year. The price currently implies -2.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nissan (NISA) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Nissan (-2.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nissan (NISA)?
The free-cash-flow yield on the price is 28.52 %: that much free cash flow Nissan produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nissan (NISA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nissan it is 16.51 ILA per share (as of Sep 24, 2026), against a price of 9.34 ILA. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Nissan stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NISA trades below its calculated fair value: price 9.34 ILA, fair value 16.51 ILA, a gap of about +77% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NISA?
No. The price is what the market pays today (9.34 ILA); the fair value is what the company's own numbers justify (16.51 ILA). For Nissan the two are 7.16 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Nissan worth?
The market values Nissan at about 84.9M ILA (market capitalisation, as of Sep 24, 2026). Per share that is 9.34 ILA; our models calculate a fair value of 16.51 ILA per share.
What do the bullish and bearish scenarios say about NISA?
Our models span a range for Nissan: cautious scenario 12.89 ILA, base 16.51 ILA, optimistic 18.50 ILA per share (as of Sep 24, 2026, price 9.34 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NISA?
Nissan trades at a price-to-earnings ratio of 21.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 16.51 ILA is built from several models across several years. Other multiples: P/B 0.2, P/S 0.0, EV/EBITDA 1.0.
How solid is the balance sheet of Nissan (NISA)?
Balance-sheet figures for Nissan (as of Sep 24, 2026): return on equity 2.5%, debt of 0.18 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is NISA from its 52-week high?
Nissan trades at 9.34 ILA, about 16% below its 52-week high of 11.08 ILA and 35% above the low of 6.90 ILA (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 16.51 ILA is for.
Which stocks are comparable to Nissan?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nissan stock attractive at the current price?
The data as of Sep 24, 2026: price 9.34 ILA, calculated fair value 16.51 ILA (+77%), Quality Score 46/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NISA calculated?
We run Nissan through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 16.51 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Nissan currently trades 77 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nissan (NISA)?
The closing price on Sep 24, 2026 was 9.34 ILA. Our model-based fair value is 16.51 ILA, about +77% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nissan right now?
The price is below even our cautious bear case (12.89 ILA). The market is more pessimistic than our downside scenario. Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Nissan (NISA) come from?
Earnings per share at Nissan grew −9.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.5 %, EBIT margin −9.4 %, tax rate +0.8 %, residual (interest, one-offs) −6.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Nissan

How large is the market capitalisation of Nissan (NISA)?
The market capitalisation of Nissan is 84.9M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nissan (NISA)?
The price-to-sales ratio of Nissan is 0.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nissan (NISA)?
Earnings per share at Nissan are 0.4300 ILA (price ÷ EPS = P/E 21.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Nissan (NISA)?
The dividend yield of Nissan is 0.2% (payout 5.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Nissan (NISA)?
The net margin of Nissan is 0.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nissan (NISA)?
The return on equity (ROE) of Nissan is 2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nissan (NISA)?
On an EBIT basis the return on assets of Nissan is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nissan (NISA)?
The operating margin of Nissan is −1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nissan (NISA)?
Revenue at Nissan is growing −7.5% versus a year earlier (3y avg −1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nissan (NISA)?
Earnings per share at Nissan are growing +68.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nissan (NISA) carry?
The net debt of Nissan is 172M ILA (fiscal year 2025, ≈ 7.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Nissan in the live analysis

One click puts Nissan on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.